Lee Danner & Bass Inc. Invests $17.70 Million in Encompass Health Corporation $EHC

Lee Danner & Bass Inc. acquired a new stake in shares of Encompass Health Corporation (NYSE:EHC) during the first quarter, HoldingsChannel reports. The fund acquired 183,000 shares of the company’s stock, valued at approximately $17,702,000. Encompass Health makes up approximately 1.1% of Lee Danner & Bass Inc.’s holdings, making the stock its 23rd largest holding.

Other hedge funds also recently made changes to their positions in the company. WPG Advisers LLC increased its holdings in Encompass Health by 73.3% in the 4th quarter. WPG Advisers LLC now owns 324 shares of the company’s stock worth $34,000 after acquiring an additional 137 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in Encompass Health during the fourth quarter valued at approximately $37,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Encompass Health by 36,200.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock worth $46,000 after purchasing an additional 362 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in shares of Encompass Health in the fourth quarter worth $55,000. Finally, Covestor Ltd increased its stake in shares of Encompass Health by 24.4% in the fourth quarter. Covestor Ltd now owns 540 shares of the company’s stock worth $57,000 after purchasing an additional 106 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Encompass Health

In other news, EVP Patrick William Tuer sold 682 shares of Encompass Health stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $104.56, for a total value of $71,309.92. Following the sale, the executive vice president directly owned 24,755 shares of the company’s stock, valued at approximately $2,588,382.80. The trade was a 2.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.80% of the stock is currently owned by insiders.

Encompass Health Price Performance

EHC stock opened at $106.48 on Friday. Encompass Health Corporation has a one year low of $92.77 and a one year high of $127.99. The company’s fifty day moving average price is $103.10 and its 200-day moving average price is $103.43. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.17 and a current ratio of 1.17. The company has a market capitalization of $10.56 billion, a PE ratio of 17.78, a price-to-earnings-growth ratio of 2.32 and a beta of 0.74.

Encompass Health (NYSE:EHC) last issued its earnings results on Thursday, April 30th. The company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. Encompass Health’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.37 earnings per share. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. On average, equities analysts anticipate that Encompass Health Corporation will post 5.97 EPS for the current fiscal year.

Encompass Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st will be given a dividend of $0.19 per share. The ex-dividend date is Wednesday, July 1st. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s dividend payout ratio (DPR) is presently 12.69%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Barclays cut their price target on Encompass Health from $153.00 to $140.00 and set an “overweight” rating for the company in a research note on Tuesday, May 5th. Leerink Partners set a $152.00 price objective on Encompass Health in a research report on Friday, May 22nd. Weiss Ratings lowered Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, June 26th. Finally, TD Cowen started coverage on Encompass Health in a research report on Thursday, May 28th. They set a “buy” rating and a $125.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, Encompass Health presently has an average rating of “Moderate Buy” and a consensus price target of $143.86.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.